Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Results from NRG LU005 in JCO ASCO – phase III trial of chemoradiation with or without concurrent then maintenance atezolizumab.
No difference in survival (OS 31.1 vs 36.1m, HR 1.03) or PFS (12.1 vs 11.4m, HR 0.98). Main difference from ADRIATIC is timing, which is everything.
A concurrent approach had the potential to increase the impact by avoiding the attrition after/during chemoradiation, addressing a larger population. But lack of benefit here, in the context of the negative PACIFIC2 study, destroys the strategy.”
Title: Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005
Authors: Kristin A. Higgins, Chen Hu, Helen J. Ross, Salma K. Jabbour, David E. Kozono, Taofeek K. Owonikoko, Timothy A. Ritter, Terence M. Williams, James Welsh, Jeffry P. Simko, B Movsas, Canhua Xiao, Kyoichi Kaira, Amit K. Gupta, Pranshu Mohindra, Elie G. Dib, Jeremy Brownstein, Stephen Chun, Charles S. Kuzma, Rupesh Kotecha, Adedayo A. Onitilo, Yuhchyau Chen, Thomas E. Stinchcombe, Xiaofei Wang, Rebecca Paulus, Jeffrey D. Bradley
You can read the full article in JCO ASCO.
More posts about SCLC.